References
- Angioli R, Plotti F, Capriglione S, et al (2013). Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?. Gynecol Oncol, 128, 579-83. https://doi.org/10.1016/j.ygyno.2012.11.040
- Avril N, Sassen S, Schmalfeldt B, et al (2005). Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol, 23, 7445-53. https://doi.org/10.1200/JCO.2005.06.965
- Bold HB, Conover CA (2011). Overexpression of pregnancyassociated plasma protein-A in ovarian cancer. Endocrinology, 152, 1470-8. https://doi.org/10.1210/en.2010-1095
- Chen JW, Ledet T, Orskov H, et al (2003). A high sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab, 284, 1149-55. https://doi.org/10.1152/ajpendo.00410.2002
- Eckstein N, Servan K, Hildebrandt B, et al (2009). Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res, 69, 29996-3003.
- Feigenberg T, Clarke B, Virtanen C, et al (2014). Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int, 367103.doi: 10/1155/2014/367103.
- Feng Z, Wen H, Bi R, et al (2016). Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients, BMC Cancer, 16, 43. https://doi.org/10.1186/s12885-016-2070-2
- Firth SM, Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev, 23, 824-54. https://doi.org/10.1210/er.2001-0033
- Gasowska-Bodnar A, Bodnar L, Dabek A, et al (2014). Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy. Int J Gynecol Cancer, 24, 687-96. https://doi.org/10.1097/IGC.0000000000000108
- Huang GS, Brouwer-Visser J, Ramirez MJ, et al (2010). Insulinlike growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res, 16, 2999-3010. https://doi.org/10.1158/1078-0432.CCR-09-3233
- Morimoto A, Nagao S, Kogiku A, et al (2016). A preoperative low cancer antigen 125 level (<25.8 mg/dL) is useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer. Jpn J Clin Oncol, 46, 517-21. https://doi.org/10.1093/jjco/hyw029
- Samani AA, Yakar S, LeRoith D, Brodt P (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insight. Endocr Rev, 28, 20-47. https://doi.org/10.1210/er.2006-0001
- Slipicevic A, Oy GF, Askildt IC, et al (2009). Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol, 40, 527-37. https://doi.org/10.1016/j.humpath.2008.10.003
- Spirina LV, Bochkareva NV, Kondakova IV, et al (2012). Regulation of insulin-like growth NF-kB proteasome system in endometrial cancer. Mol Biol (Mosk), 46, 452-60.
- Sodek KL, Murphy KJ, Brown TJ, Rinquette MJ (2012). Cellcell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev, 31, 397-414. https://doi.org/10.1007/s10555-012-9351-2
- Stadlmann S, Amberger A, Pollheimer J, et al (2005). Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol, 97, 784-9. https://doi.org/10.1016/j.ygyno.2005.02.017
- Thomsen J, Hjortebjerg R, Espelund U, et al (2015). PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. Oncotarget, 6, 32266-78. https://doi.org/10.18632/oncotarget.5010
- Verhaak RG, Tamayo P, Yang JY, et al (2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest, 123, 517-25.
- Wang F, Ye Y, Xu X, et al (2013). CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res, 6, 14. https://doi.org/10.1186/1757-2215-6-14
- Weinberg LE, Rodriguez G, Hurteau JA, et al (2010). The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol, 101, 334-43. https://doi.org/10.1002/jso.21482
- Yunusova NV, Spirina LV, Kondakova IV, et al. (2013). The relationship of metalloproteinase PAPP-A expression with the expression of growth and transcriptional factors in endometrial cancer. Biol Bull, 40, 253-9. https://doi.org/10.1134/S1062359013030114
-
Yunusova NV, Kondakova IV, Kolomiets LA, et al (2015). The insulin-like growth factors system in ovarian cancer metastasis: the relation with p45 Ser
${\beta1$ -catenin. Molekulyrnaya Meditsina, 4, 17-22. [in Russian]. - Yunusova NV, Spirina LV, Frolova AE, et al (2016). Association of IGFBP-6 expression with metabolic syndrome and with adiponectin and IGF-IR receptor levels in colorectal cancer. Asian Pac J Cancer Prev, 17, 3963-9.